ORKA
Oruka Therapeutics, Inc.
$84.40
-0.10 (-0.12%)
At close · Jul 8
Market Cap
$5.27B
Shares
60,312,101
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$84.40
Open$84.50
Day$81.19–87.23
52W$12.84–97.78
Avg vol 30d1.6M
Short int6.9M · 11.4% float · 6.1d
Short vol60%
Last earningsApr 30, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+96%
above
Price vs 50-day avg
+21%
above
RSI (14)
59
neutral
MACD trend
Negative
52-week position
84%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+32%
trailing
6-month return
+169%
trailing
YTD return
+178%
this year
Relative strength
+162%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $70 › 200d $43 — 50d above 200d
Institutional flow
Accumulating
4 of 184 funds reported for Jun 30 · net +2.9K sh shares · +2 new
Insider flow
Distributing
Net -$310.7M over 90 days · 100% sells
Short interest
Rising
11.44% of float · ▲ +8.2% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
184 holders — near 1-yr high, broad support
Squeeze score
88
high risk · 0–100
Fundamentals
EPS growth
+13%
Y/Y
Free cash flow
$-88.4M
Balance sheet
$46.9M
net cash
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
6.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+96%
Bullish
Price vs 50-day avg
+21%
Bullish
RSI (14)
59
Neutral
MACD trend
Negative
Bearish
52-week position
84%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $70 › 200d $43 — 50d above 200d
Institutional flow
Accumulating
4 of 184 funds reported for Jun 30 · net +2.9K sh shares · +2 new
Insider flow
Distributing
Net -$310.7M over 90 days · 100% sells
Short interest
Rising
11.44% of float · ▲ +8.2% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
184 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $13
Now $84 · 84%
52-wk high $98
vs 200-day avg +96%
vs 50-day avg +21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ORKA
this stock
Oruka Therapeutics, Inc.
|
$5.27B | +178.5% | — | — | 11.4% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ORKA | -11.3% | +31.8% | +169.3% | -11.3% | +178.5% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -11.1% | +30.9% | +161.9% | -11.1% | +169.2% |
Capital returns
Latest dividend
$19.356
/ share · ex Aug 29, 2024
Paid (TTM)
$0.00
/ share · 0 payouts
Dividend yield (TTM, derived)
— · no payout in the trailing year
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.